SciBase

Exciting news from SciBase! A recent study published by researchers at Koç University in Istanbul has shown promising results using EIS to monitor treatment outcomes in a young patient with severe atopic dermatitis. The study highlights the potential of Nevisense in evaluating treatment efficacy and improving patient outcomes in dermatology. We are proud to be at the forefront of innovation in healthcare and look forward to the potential impact our platform can have in improving patients' lives.
The full article can be found here: https://doi.org/10.24953/turkjpediatr.2024.4902

In collaboration with the SKIN Research Group, this new study aims to deepen the investigation of Electrical Impedance Spectroscopy (EIS) as an innovative tool for the early identification of infants at risk of developing atopic conditions, including atopic dermatitis, asthma, and hay fever.
Read the PM in full: https://investors.scibase.se/en/press/scibase-announces-collaboration-prediction-atopic-dermatitis-infants-2279519

SciBase announces sale of Nevisense to National Institutes of Health in US! This represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research.
Read the release in full:
https://investors.scibase.se/en/press/scibase-announces-sale-nevisense-nih-us-2267312

SciBase announces today a partnership with Seraly Dermatology in Pittsburgh, Pennsylvania. The strategic collaboration will allow SciBase to continue to broaden access to the Nevisense test to patients across the US, and further their commitment to the early detection of melanoma, when the disease is almost 100% curable. Seraly Dermatology will integrate several Nevisense systems into their skin cancer detection workflow.
https://investors.scibase.se/en/press/scibase-expands-new-market-pennsylvania-and-receives-first-order-large-dermatology-practice

New US Consensus Report supports for its ability to significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. The report, authored by leading U.S. clinicians and scientists, evaluated multiple diagnostic tools and was published in the renowed Journal of Drugs in Dermatology.

Read the report here : https://jddonline.com/articles/advances-in-technology-melanoma-diagnosis-prognosis-an-expert-consensus-panel-S1545961624P8365X/